GGrantIndex
Sort

40,608 grants matching prostate cancer

TREATMENT DECISIONS AND PATIENT REPORTED OUTCOMES IN LOW RISK PROSTATE CANCER

$668,484
Kathryn L Taylor · Georgetown University · R01 · FY2014 · CA

Control of the immune response for cancer vaccine development

$668,432
Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

Human T Cell Responses to Tumor Antigens for Cancer Vaccine Development

$668,432
Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

Biology and vulnerabilities of POU2F3+ tuft cell-like carcinomas

$668,427
Christopher Vakoc · Cold Spring Harbor Laboratory · R01 · FY2024 · CA

Multiscale Modeling of Bone Environment Responses to Metastatic Prostate Cancer

$668,427
David Basanta Gutierrez · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2018 · CA

Common biology underlying pleiotropic breast, prostate and ovarian cancer risk loci

$668,422
Simon Andrew Gayther · Cedars-Sinai Medical Center · R01 · FY2022 · CA

Genetic Aspects Of Viral Oncogenesis In Wild Mouse Species

$668,391
Christine Kozak · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI

Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate Cancer

$668,323
Timothy C Thompson · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA

Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate Cancer

$668,323
Timothy C Thompson · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA

Improving Cancer Outcomes for African-Americans

$668,211
New Hanover Regional Medical Center · U56 · FY2005 · CA

Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell Therapy

$668,089
Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2019 · CA

Augmenting PSMA expression to enhance PSMA directed therapeutic efficacy

$668,068
Michael C Haffner · Fred Hutchinson Cancer Center · R37 · FY2025 · CA

Biological Functions of Chromosomal Proteins

$668,049
Michael Bustin · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA

Genetic Susceptibility And The Environment In Cancer Risk

$668,041
Jack A Taylor · National Institute Of Environmental Health Sciences · Z01 · FY2008 · ES

Role of HSP90 Family Chaperone Proteins in Cellular Signal Transduction

$668,014
Leonard Neckers · Division Of Clinical Sciences - Nci · ZIA · FY2014 · CA

Next Gen Targeted nanoparticles for Inhibiting Gli2 in Bone Metastatic Tumors

$667,924
Julie A Sterling · Vanderbilt University Medical Center · R01 · FY2023 · CA

Role of Neurotrophins in the Development of the Mammalian Nervous System

$667,915
Lino Tessarollo · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA

The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab

$667,617
Jason S Lewis · Sloan-Kettering Inst Can Research · R01 · FY2017 · CA

Research Program

$667,602
Alison Meredith Buttenheim · University Of Pennsylvania · P50 · FY2021 · CA

Application of MAGNet Tools to Gene Regulatory Networks in Cancer

$667,585
Chris Sander · Sloan-Kettering Inst Can Research · R01 · FY2010 · CA

Evaluation of Transperineal Biopsy under Local Anesthesia, a Novel approach to Decrease Post-Biopsy Infections and Improve Cancer Detection

$667,582
Jim Hu · Weill Medical Coll Of Cornell Univ · R01 · FY2021 · CA

Physician Assistance Technology in Image-guided Robotic Intervention of Prostate

$667,541
Nobuhiko Hata · Brigham And Women'S Hospital · R01 · FY2022 · EB

MRI Imaging and Genetic Signatures to Manage Prostate Cancer Overdiagnosis

$667,475
Alan Pollack · University Of Miami School Of Medicine · R01 · FY2014 · CA

Mouse Cancer Models for Integrated Tissue/Serum Proteomics and Molecular Imaging

$667,466
Sanjiv S Gambhir · Stanford University · U54 · FY2009 · CA

Pilot study of an implantable microdevice to test multiple drug responses in prostate cancer patients

$667,356
Oliver Jonas · Brigham And Women'S Hospital · R01 · FY2022 · CA